Table 2. Characteristics of patients involved in assessment of 5-Fu sensitivity or resistance.
| Patient | Age (years) | Sex | Stage | Histology | Chemotherapy |
| P1631# | 66 | M | IVA | Adenocarcinoma | 5-Fu + Irinotecan + Oxaliplatin + Bevacizumab |
| P1692 | 61 | F | IVA | Adenocarcinoma | 5-Fu + Irinotecan + Oxaliplatin + Bevacizumab |
| P1699 | 78 | F | IVA | Mucus adenocarcinoma | 5-Fu + Oxaliplatin + Bevacizumab |
| P1804 | 21 | F | IIIC | Mucus adenocarcinoma | 5-Fu + Irinotecan + Oxaliplatin |
| P1822 | 76 | M | IVB | Adenocarcinoma | 5-Fu + Irinotecan + Oxaliplatin + Bevacizumab |
| P1863# | 47 | F | IVB | Mucus adenocarcinoma | 5-Fu + Irinotecan + Oxaliplatin + Bevacizumab |
| P1893 | 55 | M | IVA | Adenocarcinoma | 5-Fu + Oxaliplatin |
| P1957# | 55 | M | IVB | Adenocarcinoma | 5-Fu + Irinotecan + Oxaliplatin + Cetuximab |
| P1977# | 51 | F | IVB | Adenocarcinoma | 5-Fu + Irinotecan + Oxaliplatin + Bevacizumab |
| P2132# | 55 | M | IVB | Adenocarcinoma | 5-Fu + Irinotecan + Oxaliplatin + Bevacizumab |
| P2167 | 66 | M | IVA | Adenocarcinoma | 5-Fu + Irinotecan + Oxaliplatin + Bevacizumab |
| P2180# | 53 | F | IVB | Adenocarcinoma | 5-Fu + Oxaliplatin |
| P2186# | 65 | M | IIIC | Adenocarcinoma | 5-Fu + Irinotecan + Oxaliplatin |
| P2286# | 59 | M | IVA | Adenocarcinoma | 5-Fu + Irinotecan + Oxaliplatin + Cetuximab + Bevacizumab |
| P2295# | 48 | M | IIIC | Adenocarcinoma | 5-Fu + Irinotecan + Oxaliplatin + Bevacizumab |
| P2338 | 66 | M | IVB | Adenocarcinoma | 5-Fu + Irinotecan + Oxaliplatin + Cetuximab |
| P2357 | 70 | M | IIIB | Adenocarcinoma | 5-Fu + Irinotecan + Bevacizumab |
| P2653 | 65 | M | IIIC | Adenocarcinoma | 5-Fu + Irinotecan + Oxaliplatin + Cetuximab |
#Refers to colorectal cancer patients resistant to 5-Fu.